Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Carcinoma of the Breast Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

NCT03379428
View directory record Official record
Conditions
Breast Neoplasms, Malignant Neoplasm of Breast
Interventions
Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg, Ibrutinib 420 mg
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Women With Stage IV Breast Cancer

NCT00027807
View directory record Official record
Conditions
Breast Cancer
Interventions
Aldesleukin, Sargramostim, therapeutic autologous lymphocytes
Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer

NCT02850536
View directory record Official record
Conditions
Liver Metastases
Interventions
anti-CEA CAR-T cells
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Jul 21, 2026, 4:19 AM EDT
Completed No phase listed Observational

A Cost-Effective Handheld Breast Scanner for Use in Low Resource Environments: A Validation Study

NCT02814292
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

NCT02448771
View directory record Official record
Conditions
Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
Interventions
Palbociclib, Bazedoxifene
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Jul 21, 2026, 4:19 AM EDT
Active, not recruiting Phase 1 Interventional

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

NCT02826434
View directory record Official record
Conditions
Breast Cancer
Interventions
PVX-410, Durvalumab, Hiltonol
Biological · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Not applicable Interventional

S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer

NCT00031772
View directory record Official record
Conditions
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
108
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jul 21, 2026, 4:19 AM EDT
Not listed Not applicable Interventional

21DIF039: Prone to Supine Breast MRI II, P2S2 Breast MRI Trial

NCT05131607
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Supine MRI
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Phase 4 Interventional Results available

Quantitative Subharmonic Breast Imaging

NCT01490892
View directory record Official record
Conditions
Breast Cancer
Interventions
3D HI and SHI of UCA
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 21, 2026, 4:19 AM EDT
Recruiting Phase 2 Interventional

Study of Aerobic Training for People Receiving Treatment for Breast Cancer

NCT05716893
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma
Interventions
Adaptive Aerobic Training/AT Dosing, Standard (fixed) Aerobic Training/AT dosing
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 21, 2026, 4:19 AM EDT
Not listed Not applicable Interventional

Efficacy of Point Of Service Testing in MBC

NCT03983577
View directory record Official record
Conditions
Metastatic Cancer, Breast Cancer
Interventions
Point of service delivery model
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

NCT00951665
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
paclitaxel, pertuzumab [Perjeta], trastuzumab emtansine [Kadcyla]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Jul 21, 2026, 4:19 AM EDT
Terminated Phase 1 Interventional Results available

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

NCT02561832
View directory record Official record
Conditions
Breast Cancer
Interventions
Olaparib, Carboplatin, Anthracycline, Cyclophosphamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
New York, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors

NCT03592121
View directory record Official record
Conditions
Sexual Dysfunction, Sexual Arousal Disorder, Sexual Dysfunction, Physiological, Breast Cancer, Nipple Disorder, Neuropathy, Cancer of Breast
Interventions
AB-101, Placebo
Drug
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Ixabepilone + Carboplatin Metastatic Breast Cancer

NCT01075100
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ixabepilone, Carboplatin
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
59
States / cities
Phoenix, Arizona • Sedona, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Phase 1 Interventional

ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer

NCT02632071
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Carcinoma
Interventions
ACY-1215, Nab-paclitaxel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Not applicable Interventional

Emotions Immunology and Breast Cancer

NCT03609671
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, Emotions, Immunology
Interventions
Standard of Care + Experimental Individualized Therapy, Control: Standard of Care
Behavioral · Other
Lead sponsor
Luz A. Venta, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Acupuncture for Chronic Lymphedema

NCT01706081
View directory record Official record
Conditions
Breast Cancer With Chronic Lymphedema
Interventions
Acupuncture, Wait-list
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Jul 21, 2026, 4:19 AM EDT
Completed No phase listed Observational

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

NCT01706432
View directory record Official record
Conditions
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
Interventions
hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 21, 2026, 4:19 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 21, 2026, 4:19 AM EDT
Terminated Phase 3 Interventional Results available

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

NCT02927249
View directory record Official record
Conditions
Node Positive HER2 Negative Breast Cancer
Interventions
Placebo, Aspirin
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1426
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Jul 21, 2026, 4:19 AM EDT
Completed No phase listed Observational

Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging

NCT01060085
View directory record Official record
Conditions
Ductal Carcinoma In Situ, Invasive Breast Cancer
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
30 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jul 21, 2026, 4:19 AM EDT
Active, not recruiting Not applicable Interventional

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

NCT02603341
View directory record Official record
Conditions
Breast Cancer
Interventions
Photon, Proton
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 21, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

NCT02614794
View directory record Official record
Conditions
HER2 Positive Breast Cancer
Interventions
tucatinib, capecitabine, trastuzumab, placebo
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 21, 2026, 4:19 AM EDT